CORCEPT THERAPEUTICS INC: insider trades · United States · SEC (Form 4)

About CORCEPT THERAPEUTICS INC

Corcept Therapeutics Incorporated (NASDAQ: CORT) is a commercial-stage biopharmaceutical company headquartered in Redwood City, California, United States. Founded in May 1998 and incorporated in Delaware, the company was built around a focused scientific thesis: modulating cortisol and the glucocorticoid receptor to address serious endocrine and oncology disorders. For international investors, Corcept is best understood as a specialty healthcare name with a hybrid profile: it has an existing commercial product base, but it also retains meaningful development-stage upside tied to clinical and regulatory milestones. The company’s legacy franchise is Korlym® (mifepristone), which Corcept describes as the first FDA-approved medicine for endogenous Cushing’s syndrome. Korlym established the firm’s commercial platform and remains central to its endocrinology business. Corcept’s broader pipeline is anchored by relacorilant, a selective glucocorticoid receptor antagonist designed to exploit the biology of cortisol in multiple disease settings. In 2026, Corcept achieved a major strategic inflection point when the FDA approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. That approval materially broadens the company’s addressable market beyond Cushing’s syndrome and gives Corcept an approved oncology product alongside its endocrine franchise. From a competitive standpoint, Corcept occupies a differentiated niche rather than competing as a broad-based pharma company. Its advantage lies in deep expertise in cortisol modulation, a therapeutic mechanism that can support both commercial durability and pipeline expansion if clinical data continue to validate the platform. At the same time, the company remains highly dependent on a small number of programs, which makes it sensitive to trial outcomes, regulatory timing, label scope, reimbursement dynamics, and post-approval execution. The concentration risk is offset, however, by the potential for relacorilant to become a meaningful second growth engine. Operationally, Corcept is primarily US-centric, with its commercial, research, and regulatory activities centered in the United States, while the oncology opportunity is also being developed for broader international reach. Recent highlights include the FDA filing and subsequent approval path for relacorilant in ovarian cancer, the continuing FDA review of relacorilant for hypercortisolism/Cushing’s syndrome, and positive clinical data supporting the broader cortisol-modulation thesis. In short, Corcept on the NASDAQ in the United States remains a catalyst-driven healthcare stock where valuation is likely to be driven by product adoption, label expansion, and execution across a focused pipeline.